Hemoperfusion

Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Emory Healthcare, Sepsis, Conference, SAMI, Motivation, Clinical professor, Partnership, Patient, EAA, Mayo Clinic, Mortality, Septic shock, EDEN, University, Spectral, Intensive care unit, Critical care, PMX, AME Publishing Company, TSX, Clinical trial, Nephrology, ICU, FDA, UCLA, Baxter, Marketing, Economics, Hemoperfusion, Pharmaceutical industry

TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.
  • Dr. John Kellum, Chief Medical Officer of Spectral Medical, stated, “We have witnessed robust enrollment activity to start 2024.
  • addition of two new trial sites in the fourth quarter – the Mayo Clinic and Emory Healthcare.
  • The Company concluded the 2023 year with cash of $2,952,000 compared to $8,414,000 cash on hand as of December 31, 2022.

Spectral Medical Announces First Quarter Results and Provides Corporate Update

Retrieved on: 
Friday, May 12, 2023
University, SAPS, Observational study, Marketing, Baxter, University of California, San Francisco, Clinical trial, Research, Septic shock, Sepsis, Hemoperfusion, ISAC, ESS, Patient, UCSF, PMX, Management, TSX, Mortality, ICU, EDEN, FDA, Pharmaceutical industry, Nursing, Fine chemical, Cryptocurrency

TORONTO, May 12, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • TORONTO, May 12, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2023 and provided a corporate update.
  • Importantly, Tigris mortality data continues to exceed our expectations and has been consistent with our recent announcement of the EUPHAS-2 study results .
  • Transition activities are progressing well, with full change from the incumbent CRO expected by the end of the second quarter.
  • The Company concluded the first quarter of 2023 with cash of $4,886,000 compared to $8,414,000 of cash on hand as of December 31, 2022.

Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update

Retrieved on: 
Friday, March 24, 2023
International joint venture, Cras, De novo, Marketing, Public, Dialysis, Hemoperfusion, ESS, Medical University of South Carolina, Patient, Medical device, Intensive care unit, Software, University, Baxter, Research, MDSAP, Sepsis, Certification, UCSF, TSX, EDEN, FDA, SAMI, Observational study, COVID-19, PMX, Contract research organization, MUSC, Mortality, Breakthrough, Lipopolysaccharide, University of California, San Francisco, Clinical trial, Medical school, Septic shock, Joint venture, Infomed, ICU, Pharmaceutical industry, Silviculture, Nursing, Spectral

TORONTO, March 24, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • Importantly, we are in the process of engaging a new Contract Research Organization (“CRO”) to oversee the Tigris trial.
  • The new company, i-Dialco, is exclusively focused on advancing commercialization of the SAMI and DIMI dialysis devices in the North American markets.
  • We anticipate our initiatives aimed at enhancing trial recruitment and enrollment will assist in completion of Tigris as expeditiously as possible.
  • With the establishment of i-Dialco, the previous Dialco operations were considered discontinued as at December 31, 2022.

Global Blood Purification Devices Market Report 2023: Developments in the Absorption, Filtration, and Dialysis Processes Fuel Expansion - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Surgery, Health, Medical Devices, Hospital, Blood, Hypertension, Location, Porter's five forces analysis, Absorption, Kidney failure, Dialysis, Asahi Kasei, Competition, Baxter International, Adsorption, Continuity, Cytosorbents Corporation, Growth, Kidney, Diabetes, SWOT, Filtration, Fresenius, Incidence, USD, D, COVID-19, Pharmaceutical industry, Medical device, Hemoperfusion, Haemonetics, Hemodialysis, Application

The Global Blood Purification Devices Market was valued at USD 13.65 billion in the year 2021.

Key Points: 
  • The Global Blood Purification Devices Market was valued at USD 13.65 billion in the year 2021.
  • Americas region is estimated to hold the maximum share in global Blood Purification Devices followed by Europe & APAC.
  • The report analyses the Blood Purification Devices Market by Application - (Continuous Blood Purification, Hemodialysis, Hemoperfusion).
  • The report analyses the Blood Purification Devices Market by End Users - (Hospitals & Clinics, Dialysis Centres, Others).

Spectral Medical Provides Update on Tigris Clinical Trial and Other Business Developments

Retrieved on: 
Thursday, January 12, 2023
Medical school, Hospital, PMX, Acute, Medical University of South Carolina, Hemoperfusion, Standard of care, Dialysis, EDEN, TSX, FDA, Total, Randomized controlled trial, Knowledge, Partnership, EAA, SAMI, Death, Marketing, Lipopolysaccharide, Patient, Sepsis, Observational study, Mortality, Clinical trial, Intensive care unit, Baxter, CDC, Septic shock, Pharmaceutical industry, Health insurance, Q4

TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided a business update focusing on Tigris, the Company’s follow-on study designed to build on knowledge gained from the earlier EUPHRATES trial, which evaluated the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. The Tigris trial end point is a reduction in the 28-day mortality in subjects with septic shock using the PMX hemoperfusion cartridge versus standard of care.

Key Points: 
  • The Tigris trial end point is a reduction in the 28-day mortality in subjects with septic shock using the PMX hemoperfusion cartridge versus standard of care.
  • Chris Seto, Chief Executive Officer of Spectral Medical, commented, “We continue to aggressively advance our Tigris trial with 50 of the 150 total patients now enrolled and randomized in the study.
  • Moreover, we have seen a 30-40% increase in sepsis cases at our trial sites compared to last summer.
  • To meet final trial enrollment in 2023, we estimate the need for approximately 20 productive trial sites.

Spectral Medical Announces Strategic Joint Venture With Infomed to Accelerate Commercialization of Dimi and Sami Dialysis Devices

Retrieved on: 
Tuesday, December 13, 2022
Septic shock, Dialysis, PMX, Peritoneal dialysis, Renal replacement therapy, Hemoperfusion, Software, FDA, SAMI, Hospital, Plasmapheresis, Sepsis, Toronto Stock Exchange, News, EDT, Intelligence, Hemofiltration, Knowledge, Overload, Ultrafiltration, International joint venture, Joint venture, Certification, TSX, MDSAP, Growth, Medical device, U.S. FDA, Risk, Chronic kidney disease, Patient, Health Canada, Pharmaceutical industry, Infomed, Spectral

The new joint venture company, i-Dialco Inc. (“i-Dialco” or the “Joint Venture”)), will be exclusively focused on advancing commercialization of the SAMI and DIMI dialysis devices in the North American markets.

Key Points: 
  • The new joint venture company, i-Dialco Inc. (“i-Dialco” or the “Joint Venture”)), will be exclusively focused on advancing commercialization of the SAMI and DIMI dialysis devices in the North American markets.
  • Under the Joint Venture, Spectral will contribute SAMI and DIMI regulatory approvals, as well as transfer its Medical Device Single Audit Program (MDSAP) certification to i-Dialco.
  • Infomed, an established medical device manufacturer and original developer of the SAMI and DIMI devices, will contribute all hardware, software and certain other intellectual property to further develop the SAMI and DIMI platforms.
  • Spectral will own 30% of the Joint Venture and Infomed will own 70% of Joint Venture.

hemotune Applauded by Frost & Sullivan for Enabling Selective and Efficient Extraction of Large Compounds from Blood With Its Blood Purification Platform

Retrieved on: 
Thursday, October 27, 2022
Hemoperfusion, Frost & Sullivan, Technology, SAN, Antibody, Blood, Efficiency, Dialysis, Industry, Mortality, Patient, Frost, Cytokinesis, Achievement, Toxin (comics), Sepsis, Hospital, High-dependency unit, Creativity, Leadership, Death, Length of stay, Adsorption, Pharmaceutical industry, Medical imaging

SAN ANTONIO, Oct. 27, 2022 /PRNewswire/ -- Recently, Frost & Sullivan assessed the blood purification technology industry and, based on its findings, recognizes hemotune with the 2022 Europe Technology Innovation Leadership Award. The company developed a therapeutic blood purification platform to improve health outcomes and save patients' lives. The innovative medical device company provides ground-breaking blood purification technology based on magnetic beads, which uniquely removes large biomolecule targets with extremely high selectivity and efficiency. The system will be first used to treat sepsis, a severe life-threatening condition linked to 20% of all deaths and rising healthcare costs according to hemotune. Its solution focuses on the immunological aspects of sepsis, tackling multiple disease pathways while restoring immune balance.

Key Points: 
  • SAN ANTONIO, Oct. 27, 2022 /PRNewswire/ --Recently, Frost & Sullivan assessed the blood purification technology industry and, based on its findings, recognizes hemotune with the 2022 Europe Technology Innovation Leadership Award.
  • The company developed a therapeutic blood purification platform to improve health outcomes and save patients' lives.
  • The innovative medical device company provides ground-breaking blood purification technology based on magnetic beads, which uniquely removes large biomolecule targets with extremely high selectivity and efficiency.
  • With its strong overall performance, hemotune earns Frost & Sullivan's 2022 Europe Technology Innovation Leadership Award in the blood purification technology market.

hemotune Applauded by Frost & Sullivan for Enabling Selective and Efficient Extraction of Large Compounds from Blood With Its Blood Purification Platform

Retrieved on: 
Thursday, October 27, 2022
Hemoperfusion, Frost & Sullivan, Technology, SAN, Antibody, Blood, Efficiency, Dialysis, Industry, Mortality, Patient, Frost, Cytokinesis, Achievement, Toxin (comics), Sepsis, Hospital, High-dependency unit, Creativity, Leadership, Death, Length of stay, Adsorption, Pharmaceutical industry, Medical imaging

SAN ANTONIO, Oct. 27, 2022 /PRNewswire/ -- Recently, Frost & Sullivan assessed the blood purification technology industry and, based on its findings, recognizes hemotune with the 2022 Europe Technology Innovation Leadership Award. The company developed a therapeutic blood purification platform to improve health outcomes and save patients' lives. The innovative medical device company provides ground-breaking blood purification technology based on magnetic beads, which uniquely removes large biomolecule targets with extremely high selectivity and efficiency. The system will be first used to treat sepsis, a severe life-threatening condition linked to 20% of all deaths and rising healthcare costs according to hemotune. Its solution focuses on the immunological aspects of sepsis, tackling multiple disease pathways while restoring immune balance.

Key Points: 
  • SAN ANTONIO, Oct. 27, 2022 /PRNewswire/ --Recently, Frost & Sullivan assessed the blood purification technology industry and, based on its findings, recognizes hemotune with the 2022 Europe Technology Innovation Leadership Award.
  • The company developed a therapeutic blood purification platform to improve health outcomes and save patients' lives.
  • The innovative medical device company provides ground-breaking blood purification technology based on magnetic beads, which uniquely removes large biomolecule targets with extremely high selectivity and efficiency.
  • With its strong overall performance, hemotune earns Frost & Sullivan's 2022 Europe Technology Innovation Leadership Award in the blood purification technology market.

Spectral Medical Highlights From Vicenza Course 2022

Retrieved on: 
Thursday, July 14, 2022
PMX, EDT, Health Canada, News, EAA, Federal Food, Drug, and Cosmetic Act, TSX, Hemoperfusion, Septic shock, Company, Risk, SAMI, Patient, Polymyxin, Renal replacement therapy, Classification, Acute kidney injury, Mortality, GLOBE, Lipopolysaccharide, RRT, Spectral, Toronto Stock Exchange, Sepsis, U.S. FDA, FDA, University of Modena and Reggio Emilia, University, Biomarker, Hemofiltration, Pharmaceutical industry, Medical device

TORONTO, July 14, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (Dialco), has posted on its website a video replay from the 40th Vicenza Course on Acute Kidney Injury and Continuous Renal Replacement Therapy which featured Dr. John Kellum, Spectral Medicals CMO.

Key Points: 
  • TORONTO, July 14, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (Dialco), has posted on its website a video replay from the 40th Vicenza Course on Acute Kidney Injury and Continuous Renal Replacement Therapy which featured Dr. John Kellum, Spectral Medicals CMO.
  • In July 2022, the U.S. FDA granted Spectral Medical Breakthrough Device Designation for PMX.
  • Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy (RRT) across the dialysis spectrum.
  • While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect.

Asia Pacific Blood Purification Equipment Market 2021-2031: Industry to Grow by 6.3% CAGR - ResearchAndMarkets.com

Retrieved on: 
Monday, July 4, 2022
Medical Devices, Health, CRRT, Prevalence, COVID-19, Hemodialysis, Adoption, Health, Asia-Pacific, Pharmaceutical industry, Hemoperfusion

The "Asia Pacific Blood Purification Equipment Market 2021-2031 by Product (Hemodialysis, Blood Filtration, CRRT, Hemoperfusion, Plasma Exchange Device), Portability (Portable, Stationary), Indication, End User, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Pacific Blood Purification Equipment Market 2021-2031 by Product (Hemodialysis, Blood Filtration, CRRT, Hemoperfusion, Plasma Exchange Device), Portability (Portable, Stationary), Indication, End User, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • Asia Pacific blood purification equipment market will grow by 6.3% annually with a total addressable market cap of $72.37 billion over 2022-2031 owing to the increasing prevalence of blood-related diseases, rising geriatric population, technological innovations, growing healthcare expenditure, rising adoption of home based healthcare, and the rising health consciousness amid COVID-19 pandemic.
  • In-depth qualitative analyses include identification and investigation of the following aspects: